Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orthogen AG

www.orthogen.com

Latest From Orthogen AG

Flex Biomedical Inc.

Intra-articular injections of hyaluronic acid, which mimics the lubricating properties of natural synovial fluid and lessens friction and pain in the osteoarthritic knee joint, has become increasingly popular for treating osteoarthritis. However, of the seven formulations available in the US, none have been proven clinically superior and they have only limited long-term benefit to the patient. Flex Biomedical Inc. is working to address these concerns with a single-injection synthetic polymer alternative to HA.

Injectable Solutions for Joint and Back Pain

Injectable products that can alleviate pain and even reverse the disease process are on the horizon for treating degenerative orthopedic and spinal conditions, such as damaged articular joint cartilage and deteriorated spinal discs. With no available long-term treatment options for these conditions short of invasive surgical procedures like joint replacement or spinal fusion, injectable technologies that offer the possibility of being used upstream in the continuum of care are potential billion-dollar market opportunities. In fact, in a post health care reform environment, injectable therapies may prove to be the most cost-effective way for treating many degenerative conditions.
Medical Device

Deals Shaping the Medical Industry (3/07)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Medical Devices
    • Biomaterials
  • Pharmaceuticals
  • Therapeutic Areas
  • Inflammation
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Orthogen AG
  • Senior Management
  • Peter Wehling, Pres. & CEO
  • Contact Info
  • Orthogen AG
    Phone: (49) 700 6784 6436
    Graf Adolf Strasse 43
    Düsseldorf, D-40210
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register